A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
Pfizer
Merck Sharp & Dohme LLC
Canadian Cancer Trials Group
Providence Health & Services
National Cancer Institute (NCI)
Sun Yat-sen University
Alliance for Clinical Trials in Oncology
Jonsson Comprehensive Cancer Center
SCRI Development Innovations, LLC
Pfizer
Sun Yat-sen University
Sixth Affiliated Hospital, Sun Yat-sen University
Institut du Cancer de Montpellier - Val d'Aurelle
Universitätsmedizin Mannheim
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
City of Hope Medical Center
Alliance for Clinical Trials in Oncology
Institut Bergonié
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Pfizer
Servicio de Salud Metropolitano Sur Oriente
City of Hope Medical Center
City of Hope Medical Center